These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35217635)

  • 1. Increased retention of tau PET ligand [
    Gomar JJ; Tan G; Halpern J; Gordon ML; Greenwald B; Koppel J
    Transl Psychiatry; 2022 Feb; 12(1):82. PubMed ID: 35217635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.
    Vogel JW; Mattsson N; Iturria-Medina Y; Strandberg OT; Schöll M; Dansereau C; Villeneuve S; van der Flier WM; Scheltens P; Bellec P; Evans AC; Hansson O; Ossenkoppele R; ;
    Hum Brain Mapp; 2019 Feb; 40(2):638-651. PubMed ID: 30368979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's Disease Neuroimaging Initiative.
    Koppel J; Sunday S; Goldberg TE; Davies P; Christen E; Greenwald BS;
    Am J Geriatr Psychiatry; 2014 Jul; 22(7):698-707. PubMed ID: 23672944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of Tau Load Using [
    Golla SSV; Timmers T; Ossenkoppele R; Groot C; Verfaillie S; Scheltens P; van der Flier WM; Schwarte L; Mintun MA; Devous M; Schuit RC; Windhorst AD; Lammertsma AA; Boellaard R; van Berckel BNM; Yaqub M
    Mol Imaging Biol; 2017 Dec; 19(6):963-971. PubMed ID: 28374171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
    Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
    J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between quantitative [
    Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
    Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging tau burden in dementia with Lewy bodies using [
    Mak E; Nicastro N; Malpetti M; Savulich G; Surendranathan A; Holland N; Passamonti L; Jones PS; Carter SF; Su L; Hong YT; Fryer TD; Williams GB; Aigbirhio F; Rowe JB; O'Brien JT
    Neurobiol Aging; 2021 May; 101():172-180. PubMed ID: 33631469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontotemporal dementia with the V337M
    Spina S; Schonhaut DR; Boeve BF; Seeley WW; Ossenkoppele R; O'Neil JP; Lazaris A; Rosen HJ; Boxer AL; Perry DC; Miller BL; Dickson DW; Parisi JE; Jagust WJ; Murray ME; Rabinovici GD
    Neurology; 2017 Feb; 88(8):758-766. PubMed ID: 28130473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative
    Zhao Q; Liu M; Ha L; Zhou Y;
    Front Neurol; 2019; 10():486. PubMed ID: 31156534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining iron-related off-target binding effects of
    Langley J; Bennett IJ; Hu XP;
    Eur J Neurosci; 2024 Jul; 60(1):3614-3628. PubMed ID: 38722153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.
    Smith R; Wibom M; Pawlik D; Englund E; Hansson O
    JAMA Neurol; 2019 Mar; 76(3):310-317. PubMed ID: 30508025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease.
    Iaccarino L; Tammewar G; Ayakta N; Baker SL; Bejanin A; Boxer AL; Gorno-Tempini ML; Janabi M; Kramer JH; Lazaris A; Lockhart SN; Miller BL; Miller ZA; O'Neil JP; Ossenkoppele R; Rosen HJ; Schonhaut DR; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2018; 17():452-464. PubMed ID: 29159058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between [
    La Joie R; Bejanin A; Fagan AM; Ayakta N; Baker SL; Bourakova V; Boxer AL; Cha J; Karydas A; Jerome G; Maass A; Mensing A; Miller ZA; O'Neil JP; Pham J; Rosen HJ; Tsai R; Visani AV; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2018 Jan; 90(4):e282-e290. PubMed ID: 29282337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional [
    Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer's disease.
    Lu J; Zhang Z; Wu P; Liang X; Zhang H; Hong J; Clement C; Yen TC; Ding S; Wang M; Xiao Z; Rominger A; Shi K; Guan Y; Zuo C; Zhao Q;
    Neuroimage Clin; 2023; 38():103416. PubMed ID: 37137254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline [
    Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
    Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.